switching between tirzepatide and semaglutide glp 1 agonists GLP‐1 receptor in clinical practice: Expert consensus practical guidance Switching Between and Tirzepatide: – Transitioning Treatments: What to Expect

In a study with over 18,000 adults, those taking tirzepatide (Mounjaro) lost about 7% more weight on average than those taking semaglutide (Wegovy) over 12 months

The 30-day figure is presented as the common case rather than a universal rule, which is why the label supplied with a specific preparation is the authority on that preparation

Overall, the study provided important insights into the mechanism of action for semaglutide-induced weight loss

Fatigue is another common side effect of Semaglutide

Some patients may also experience lower intake of key nutrients such as protein, vitamin D, and B12, which are important for skin health